In light of the clinical estimation of structural gene variation, we detected that higher ERBB2 mutations and more amplification are frequently associated with a worse prognosis of cancer, regardless of whether these cancers have more ERBB2 gene copy numbers or not. This evidence concerns the gene ERBB2 and cancer.